dementia-2018-scientifictracks

17 / 17

Page 57
Notes:
conferenceseries.com
Volume 8 Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460 Dementia 2018
October 29-31, 2018
October 29-31, 2018 | Valencia, Spain
12th International Conference on
Alzheimer’s Disease & Dementia
Ranolazina decrease inflammation and oxidative stress in neural cells in primary culture
Soraya L Valles, Adrian Jorda, Martin Aldasoro, Patricia Marchio, Constanza Aldasoro, Sol Guerra-Ojeda, M Dolores Mauricio and Jose M Vila
University of Valencia, Spain
Ranolazine is a piperizene drug used in heart attack. This drug deserves not only to be clinically studied but also registered
as medicine in particular against serious diseases including cardiovascular disease and this drug has been approved by
European Medicament Agency. Our group has demonstrated a decrease of inflammation and oxidative stress in neural cells
of primary culture by adding Aβ1-42 compared with control cells. Also, in this investigation we detect neural decrease in
cell death induced by addition of the toxic peptide. Future studies looking for ranolazine action in other brain cells such as
oligodendroglia or microglia will be assayed. Also, a clinical study of patients with Alzheimer’ disease will be necessary.
Biography
Soraya L Valles are working as Assistant Professor in Department of Physiology, School of Medicine and University of Valencia, Spain. She is specialized in
biochemical and molecular biology. Her areas of research interests are discovery of novel pharmaceutical products that can be developed to novel drugs in
particular anticancer and Alzheimer’s disease and discover the pathways produced by the drugs in illness as well as elucidating and understanding the mechanisms
of action.
Soraya L Valles et al., J Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C7-054